Literature DB >> 8657920

Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.

F Dehdashti1, B A Siegel, L K Griffeth, M J Fusselman, D D Trask, A H McGuire, D J McGuire.   

Abstract

PURPOSE: To assess the ability of positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) to allow differentiation of benign from malignant intraosseous lesions.
MATERIALS AND METHODS: Twenty patients with strictly intraosseous lesions (five benign and 15 malignant [three primary and 12 metastatic]) were studied with FDG PET. The final diagnosis was confirmed with histopathologic examination in all patients. The uptake of FDG within each lesion was evaluated qualitatively as well as semiquantitatively by determination of the standardized uptake value (SUV).
RESULTS: SUV assessment of FDG accumulation within osseous lesions was superior to subjective visual analysis for discriminating benign from malignant lesions. With use of a 2.0 cutoff value for SUV, 14 of 15 malignant lesions were categorized correctly versus 12 of 15 correctly categorized by means of subjective image evaluation; four of five benign lesions were categorized correctly with both techniques.
CONCLUSION: FDG PET can aid in differentiating benign from malignant strictly intraosseous lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657920     DOI: 10.1148/radiology.200.1.8657920

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Intraosseous hemangioma arising in the clavicle.

Authors:  Yoshihiro Matsumoto; Yusuke Takahashi; Akihisa Haraguchi; Tatsuro Okamoto; Katsumi Harimaya; Tomoya Matsunobu; Makoto Endo; Yoshinao Oda; Yukihide Iwamoto
Journal:  Skeletal Radiol       Date:  2013-08-30       Impact factor: 2.199

Review 2.  False-positive FDG PET uptake--the role of PET/CT.

Authors:  Sandra J Rosenbaum; Thomas Lind; Gerald Antoch; Andreas Bockisch
Journal:  Eur Radiol       Date:  2005-12-17       Impact factor: 5.315

3.  The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

Authors:  Wendi O'Connor; Megan Quintana; Scott Smith; Monte Willis; Jordan Renner
Journal:  J Radiol Case Rep       Date:  2014-06-30

4.  Variation and repeatability of measured standardized uptake values depending on actual values: a phantom study.

Authors:  Tomohiro Kaneta; Na Sun; Matsuyoshi Ogawa; Hitoshi Iizuka; Tetsu Arisawa; Ayako Hino-Shishikura; Keisuke Yoshida; Tomio Inoue
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-11-01

Review 5.  PET/CT in primary musculoskeletal tumours: a step forward.

Authors:  A Lakkaraju; C N Patel; K M Bradley; A F Scarsbrook
Journal:  Eur Radiol       Date:  2010-06-25       Impact factor: 5.315

6.  Maxillary mesenchymal chondrosarcoma presenting with epistaxis in a child.

Authors:  Srinivas Anand Swaroop Uppaluri; Loi Hoi Yin; Giap Hean Goh
Journal:  J Radiol Case Rep       Date:  2015-08-31

7.  18FDG-PET applications for cartilage neoplasms.

Authors:  Frieda Feldman; Ronald Van Heertum; Chitra Saxena; May Parisien
Journal:  Skeletal Radiol       Date:  2005-06-04       Impact factor: 2.199

Review 8.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

9.  The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoshiaki Nakabeppu; Atsushi Tani; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2015-09-04       Impact factor: 3.039

10.  Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings.

Authors:  Larry A Binkovitz; Randal S Olshefski; Brent H Adler
Journal:  Pediatr Radiol       Date:  2003-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.